Prognostic factors associated with survival in a large cohort of gastric cancer patients resected over a decade at a single Italian center: the Cremona experience
- 68 Downloads
Incidence of gastric cancer (GC) shows different distribution in Italy, with higher incidence in the north and center. We retrospectively analyzed the clinical data of patients resected at the Hospital of Cremona between January 2007 and December 2016. Available clinical variables were linked with survival to identify possible prognostic factors.
Materials and methods
Variables analyzed were age, sex, type of surgery, site, histology, invasion, nodal status, resection margins, grade, HER2 status, Helicobacter pylori infection (neo)adjuvant chemotherapy, adjuvant chemoradiotherapy, neutrophil-to-lymphocyte ratio, number of nodes removed and type of lymphadenectomy. Overall survival (OS) was estimated by the Kaplan–Meier method and differences between groups by the log-rank test. Data on OS were analyzed by Cox regression and the final model was obtained using the step-wise method.
379 patients were considered, out of which 195 were operated from 2007 to 2011 and 184 from 2012 to 2016. Median follow-up was 25.5 months, median OS 31.3 months and time to recurrence 23.2 months. D2 resection rate increased from 36% (period 2007–2011) to 74% in 2012–2016 (p = 0.01) with a higher mean number of nodes collected (20.98 for 2007–2011 and 23.53 for 2012–2016, p = 0.040). Only 37% of patients received a postoperative treatment. At multivariate analysis, variables associated with OS were age (p = 0.002), stage (p < 0.001), resection margins status (p < 0.001), adjuvant chemotherapy (p < 0.010) and tumor location (cardia vs non-cardia) (p = 0.029).
Our analysis shows that completeness of resection and lower stage are strong predictors of long-term survival in GC, providing the rationale for adjuvant and neoadjuvant approaches (chemotherapy, radiotherapy or combined). Cardial GC has worse prognosis compared to distal cancers.
Trial registration number
Service evaluation number 256, protocol 16821/17, date 05 June 2017.
KeywordsGastric cancer Surgery Lymphadenectomy Gastric adenocarcinoma
Authors want to thank Dr. Michael Davies (Unique Language Training) for linguistic revision.
No grants supported this research project.
Compliance with ethical standards
Conflict of interest
Authors have no conflicts of interest to declare.
Informed consent was obtained from all individual participants included in the study.
Approval for this project was obtained before the start of the study from the local Institutional Review Board.
- 1.World Health Organization. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide (Version 2012). https://globocan.iarc.fr/Default.aspx. Accessed August 14, 2018.
- 3.Associazione Italiana di Oncologia Medica. I numeri del cancro in Italia AIOM-AIRTUM (Version 2017). https://www.aiom.it/fondazione-aiom/aiom-airtum-numeri-cancro-2017/aiom-airtum-numeri-cancro-2017/130211. Accessed 14 Aug 2018.
- 8.Union for International Cancer Control’s. 8th edition of the UICC TNM classification of malignant tumors (version 2018). https://www.uicc.org/8th-edition-uicc-tnm-classification-malignant-tumors-published. Accessed 14 Aug 2018.
- 10.National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology, gastric cancer (version 2.2018). Accessed 14 Aug 2018.Google Scholar
- 12.Al-Batran SE, Hofheinz RD, Pauligk C, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016;17:1697–708.CrossRefGoogle Scholar